Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).

scientific article published on 11 April 2018

Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/NEUROS/NYY108
P932PMC publication ID6500884
P698PubMed publication ID29660039

P50authorJanne KoskimäkiQ85280839
Romuald GirardQ87294525
Kelly FlemmingQ89357428
Sean P PolsterQ90469109
P2093author name stringYing Cao
Nicholas Hobson
Helen Kim
Karen Lane
Richard E Thompson
Jennifer J Majersik
Timothy Carroll
Leslie Morrison
Agnieszka Stadnik
Daniel Hanley
Issam A Awad
Nichol McBee
Robert Shenkar
Hussein A Zeineddine
James Koenig
Joseph Zabramski
P2860cites workLoss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformationsQ24314844
Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signalingQ24338286
Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutationsQ30389638
Dynamic contrast-enhanced MRI evaluation of cerebral cavernous malformationsQ30712120
Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS).Q30786918
Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data.Q31031466
Prevalence, Clinical Management, and Natural Course of Incidental Findings on Brain MR Images: The Population-based Rotterdam Scan StudyQ31110242
Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.Q31119793
Cerebral cavernous malformation: new molecular and clinical insightsQ33342264
Hemorrhage from cavernous malformations of the brain: definition and reporting standards. Angioma Alliance Scientific Advisory BoardQ33381502
Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis.Q33920720
Outcome after surgical or conservative management of cerebral cavernous malformationsQ34079287
KRIT1 protein depletion modifies endothelial cell behavior via increased vascular endothelial growth factor (VEGF) signalingQ34552843
Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mappingQ34626246
Walking after stroke. Measurement and recovery over the first 3 monthsQ69004002
Pathological heterogeneity of angiographically occult vascular malformations of the brainQ72586272
Spectrum of genotype and clinical manifestations in cerebral cavernous malformationsQ79718991
Association between disability measures and short-term health care costs following intracerebral hemorrhageQ81771623
A randomized, controlled trial of oral propranolol in infantile hemangioma.Q34668015
Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformationsQ35151828
Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.Q35167117
Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations.Q35174618
The neurology quality-of-life measurement initiativeQ35343088
Sensitivity of patients with familial cerebral cavernous malformations to therapeutic radiationQ35624537
Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation diseaseQ35693325
Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort studyQ35764796
Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout miceQ35845857
Vascular permeability in cerebral cavernous malformations.Q36267403
Defective autophagy is a key feature of cerebral cavernous malformationsQ36278717
Health related quality of life of stroke survivors: experience of a stroke unitQ36736716
Cerebral cavernous malformations: natural history and prognosis after clinical deterioration with or without hemorrhageQ36875970
Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signallingQ36892606
Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation diseaseQ37050968
Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesisQ37092450
Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations.Q37099099
Radiosurgery for angiographically occult vascular malformationsQ37466664
Rehabilitation after strokeQ37969232
Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts PanelQ38848129
KRIT1 loss of function causes a ROS-dependent upregulation of c-JunQ38873324
B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.Q38880171
Evaluation of the bioactive properties of avenanthramide analogs produced in recombinant yeast.Q38914490
Clinical determinants of long-term quality of life after strokeQ39790682
Solitary Sporadic Cerebral Cavernous Malformations: Risk Factors of First or Recurrent Symptomatic Hemorrhage and Associated Functional ImpairmentQ40811124
Natural history of intracranial cavernous malformationsQ42486712
EndMT contributes to the onset and progression of cerebral cavernous malformationsQ45333641
Platinum nanozymes recover cellular ROS homeostasis in an oxidative stress-mediated disease modelQ46604327
Quality of Life After Surgery for Cerebral Cavernoma: Brainstem Versus Nonbrainstem LocationQ47672578
Factors predisposing to clinical disability in patients with cavernous malformations of the brainQ48290193
A comparison of the clinical profile of cavernous malformations with and without associated venous malformationsQ48302819
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.Q48419319
Natural history of the cavernous angiomaQ48627465
Quality of life after brainstem cavernoma surgery in 71 patients.Q48686644
Endothelial Cells Lining Sporadic Cerebral Cavernous Malformation Cavernomas Undergo Endothelial-to-Mesenchymal TransitionQ48931961
Which is more valid for stroke patients: generic or stroke-specific quality of life measures?Q48959683
Hemorrhage risks and functional outcomes of untreated brainstem cavernous malformations.Q50666265
Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage.Q50959104
Health-related quality of life among long-term survivors of stroke : results from the Auckland Stroke Study, 1991-1992.Q51977778
Measuring quality of life in a way that is meaningful to stroke patients.Q53537651
Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion.Q54679968
P433issue4
P407language of work or nameEnglishQ1860
P304page(s)954-964
P577publication date2018-04-11
P1433published inNeurosurgeryQ7002693
P1476titleTrial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).
P478volume84

Reverse relations

cites work (P2860)
Q92884386Biomarkers of cavernous angioma with symptomatic hemorrhage
Q90085339Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites
Q90668506Predictors of Initial Presentation with Hemorrhage in Patients with Cavernous Malformations
Q92317498Symptomatic Cavernous Malformation Presenting with Seizure without Hemorrhage: Analysis of Factors Influencing Clinical Presentation

Search more.